ArticleFrontiers in molecular biosciences2026
Circulating arginine-nitric oxide pathway metabolites and nitrated fatty acids in relation to pathological features of colorectal cancer.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Colorectal cancer (CRC) is associated with metabolic and inflammatory disturbances, including alterations in the arginine-nitric oxide (NO) pathway. This study assessed serum metabolites related to the arginine-NO-nitrated fatty acid (NO₂-FA) axis in patients with CRC and examined their associations with tumor stage and pathological features. Methods: A total of 122 patients undergoing colorectal resection for CRC were prospectively enrolled, of whom 117 had complete measurements for the candidate-metabolite panel and were included in the analyses. Preoperative serum samples were analyzed using targeted LC-MS/MS. Associations between metabolite concentrations and tumor stage were evaluated using complementary exploratory modelling approaches, including ordinal regression for TNM stage, tumor extent (T), and nodal involvement (N), as well as binary logistic regression for advanced disease (TNM III-IV), angioinvasion, and neuroinvasion. Results: Among the analyzed metabolites, SDMA showed the most recurrent inverse association with pathological disease stage in the initial models. However, these associations attenuated after adjustment for age and sex and were further weakened after additional adjustment for serum creatinine, with all fully adjusted 95% confidence intervals (CIs) including unity. Thus, the observed SDMA pattern was not independent of renal function and should be regarded as hypothesis-generating rather than as a convincing stage-associated metabolic signal. In a complementary binary analysis of TNM stages III-IV versus I-II, an inverse association with SDMA persisted after adjustment only under the stepwise selection strategy. Lower agmatine concentrations were associated with higher T category under the elastic-net strategy. Under the stepwise strategy, higher ADMA concentrations were associated with lower odds of angioinvasion and neuroinvasion, whereas higher citrulline concentrations were associated with higher odds of neuroinvasion. These invasive-feature associations were not reproduced under the elastic-net strategy and should therefore be considered procedure-dependent exploratory findings. No clear association was detected between circulating nitrooleates and the analyzed pathological outcomes. Discussion: These exploratory findings identify preliminary stage-associated metabolic patterns within patients with CRC and require validation in independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.